The International Myeloma Working Group (IMWG) has recently published further consensus criteria for defining disease response in myeloma. Since the original response criteria were set in 2006, newer, more sensitive methods can now quantify myeloma cells as low as 1 in a million. Published in the Lancet Oncology, the updated criteria identify responses beyond complete response and include new response categories of minimal residual disease (MRD) negativity. They are expected to be adopted for use in clinical practice and research with immediate effect.